Year All2024202320222021202020192018201720162015201420132012201120102007 12.09.21 Syndax Pharmaceuticals Announces Closing of Global Collaboration and License Agreement for Axatilimab WALTHAM, Mass. , Dec. 9, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) announced today that the Hart-Scott-Rodino (HSR) antitrust waiting period had expired and that the parties closed the exclusive worldwide collaboration and license agreement between Syndax and Incyte to Read More 11.15.21 Syndax Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Business Update - Initiated pivotal Phase 2 portion of SNDX-5613 AUGMENT-101 trial in patients with NPM1 and MLLr acute leukemias - - Entered global collaboration with Incyte to develop and commercialize axatilimab for cGVHD and other fibrotic diseases - - Updated data from SNDX-5613 and axatilimab clinical Read More 11.08.21 Syndax to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 15, 2021 WALTHAM, Mass. , Nov. 8, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its third quarter 2021 financial Read More 11.04.21 Syndax Pharmaceuticals to Present Updated Data from SNDX-5613 and Axatilimab Clinical Programs During Oral Sessions at 63rd ASH Annual Meeting - Robust clinical activity with durable responses and no discontinuations due to treatment-related adverse events observed in Phase 1 portion of AUGMENT-101 trial of SNDX-5613 in relapsed or refractory patients with genetically-defined acute leukemias - - Phase 2 results highlight broad efficacy Read More 09.27.21 Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases - Syndax to receive $ 152 million in cash ($117 million upfront plus a $35 million equity investment, with potential for $450 million in additional milestone payments; 50:50 profit share in the U.S. and double-digit royalties on ex-U.S. sales - - The two companies expect to expand development of Read More 09.15.21 Syndax Appoints Martin H. Huber, M.D., to its Board of Directors WALTHAM, Mass. , Sept. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the expansion of its Board of Directors to nine members Read More 09.02.21 Syndax Announces Participation at Three Upcoming Investor Conferences WALTHAM, Mass. , Sept. 2, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in Read More 08.09.21 Syndax Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Business Update - Intermediate doses selected for Phase 2 portion of AUGMENT-101 trial of SNDX-5613 in patients with genetically-defined acute leukemias; updated results from Phase 1 portion anticipated in 4Q21 - - Syndax initiating frontline combination of SNDX-5613 with venetoclax and azacitidine in the Beat® Read More 08.02.21 Syndax to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 9, 2021 WALTHAM, Mass. , Aug. 2, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its second quarter 2021 financial Read More 06.28.21 SNDX-5613 Granted FDA Fast Track Designation for the Treatment of Relapsed/Refractory Acute Leukemias WALTHAM, Mass. , June 28, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Read More 06.03.21 Syndax Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference WALTHAM, Mass. , June 3, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in the Read More 05.13.21 Syndax Announces Participation in Cowen 2nd Annual Virtual Oncology Innovation Summit WALTHAM, Mass. , May 13, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in the Read More
12.09.21 Syndax Pharmaceuticals Announces Closing of Global Collaboration and License Agreement for Axatilimab WALTHAM, Mass. , Dec. 9, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) announced today that the Hart-Scott-Rodino (HSR) antitrust waiting period had expired and that the parties closed the exclusive worldwide collaboration and license agreement between Syndax and Incyte to Read More
11.15.21 Syndax Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Business Update - Initiated pivotal Phase 2 portion of SNDX-5613 AUGMENT-101 trial in patients with NPM1 and MLLr acute leukemias - - Entered global collaboration with Incyte to develop and commercialize axatilimab for cGVHD and other fibrotic diseases - - Updated data from SNDX-5613 and axatilimab clinical Read More
11.08.21 Syndax to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 15, 2021 WALTHAM, Mass. , Nov. 8, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its third quarter 2021 financial Read More
11.04.21 Syndax Pharmaceuticals to Present Updated Data from SNDX-5613 and Axatilimab Clinical Programs During Oral Sessions at 63rd ASH Annual Meeting - Robust clinical activity with durable responses and no discontinuations due to treatment-related adverse events observed in Phase 1 portion of AUGMENT-101 trial of SNDX-5613 in relapsed or refractory patients with genetically-defined acute leukemias - - Phase 2 results highlight broad efficacy Read More
09.27.21 Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases - Syndax to receive $ 152 million in cash ($117 million upfront plus a $35 million equity investment, with potential for $450 million in additional milestone payments; 50:50 profit share in the U.S. and double-digit royalties on ex-U.S. sales - - The two companies expect to expand development of Read More
09.15.21 Syndax Appoints Martin H. Huber, M.D., to its Board of Directors WALTHAM, Mass. , Sept. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the expansion of its Board of Directors to nine members Read More
09.02.21 Syndax Announces Participation at Three Upcoming Investor Conferences WALTHAM, Mass. , Sept. 2, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in Read More
08.09.21 Syndax Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Business Update - Intermediate doses selected for Phase 2 portion of AUGMENT-101 trial of SNDX-5613 in patients with genetically-defined acute leukemias; updated results from Phase 1 portion anticipated in 4Q21 - - Syndax initiating frontline combination of SNDX-5613 with venetoclax and azacitidine in the Beat® Read More
08.02.21 Syndax to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 9, 2021 WALTHAM, Mass. , Aug. 2, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its second quarter 2021 financial Read More
06.28.21 SNDX-5613 Granted FDA Fast Track Designation for the Treatment of Relapsed/Refractory Acute Leukemias WALTHAM, Mass. , June 28, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Read More
06.03.21 Syndax Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference WALTHAM, Mass. , June 3, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in the Read More
05.13.21 Syndax Announces Participation in Cowen 2nd Annual Virtual Oncology Innovation Summit WALTHAM, Mass. , May 13, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in the Read More